Stay updated on AFM13-NK vs AFM13 in Lymphoma Clinical Trial
Sign up to get notified when there's something new on the AFM13-NK vs AFM13 in Lymphoma Clinical Trial page.

Latest updates to the AFM13-NK vs AFM13 in Lymphoma Clinical Trial page
- Check6 days agoChange DetectedThe record describes a completed phase I/II study of AFM13-NK cells and AFM13 for recurrent or refractory CD30-positive lymphomas. It includes the study’s treatment plan, eligibility requirements, measured outcomes, and results.SummaryDifference62%

- Check13 days agoChange DetectedThe footer revision label changes from v3.7.2 to v3.8.0; the study record remains unavailable behind a 403 Forbidden error.SummaryDifference0.2%

- Check20 days agoChange DetectedA banner announces NIH website updates and says agencies are transitioning from the term “Artificial Intelligence” to “Super Intelligence.”SummaryDifference1%

- Check27 days agoChange DetectedThe footer revision identifier changes from v3.7.1 to v3.7.2; the page continues to display a 403 Forbidden error.SummaryDifference0.2%

- Check34 days agoChange DetectedThe footer revision identifier changed from v3.7.0 to v3.7.1.SummaryDifference0.2%

- Check55 days agoChange DetectedThe page now shows a 403 Forbidden error, replacing the expected study record with an access-denied page. This blocks access to the study information and leaves the user on an error screen instead of the study details.SummaryDifference21%

Stay in the know with updates to AFM13-NK vs AFM13 in Lymphoma Clinical Trial
Enter your email address, and we'll notify you when there's something new on the AFM13-NK vs AFM13 in Lymphoma Clinical Trial page.